- Home
- Publications
- Publication Search
- Publication Details
Title
Biologics for severe asthma and beyond
Authors
Keywords
-
Journal
PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages 108551
Publisher
Elsevier BV
Online
2023-10-30
DOI
10.1016/j.pharmthera.2023.108551
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study
- (2023) Luis García-Marcos et al. Lancet Global Health
- A2BCD: a concise guide for asthma management
- (2023) Marek Lommatzsch et al. Lancet Respiratory Medicine
- Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
- (2023) Andrew Menzies-Gow et al. Lancet Respiratory Medicine
- Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis
- (2023) Katsuyoshi Tomomatsu et al. Scientific Reports
- Response to biologics and clinical remission in the adult GAN severe asthma registry cohort
- (2023) Katrin Milger et al. Journal of Allergy and Clinical Immunology-In Practice
- Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)
- (2023) Katrin Milger et al. PNEUMOLOGIE
- Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients
- (2023) Dennis Thomas et al. ALLERGY
- Biologic Therapies for Severe Asthma
- (2022) Guy G. Brusselle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
- (2022) Andrew N Menzies-Gow et al. Journal of Asthma and Allergy
- Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
- (2022) Luis A Pérez de Llano et al. Journal of Asthma and Allergy
- Safety of combining biologics in severe asthma: asthma‐related and unrelated combinations
- (2022) Marek Lommatzsch et al. ALLERGY
- Disease-modifying anti-asthmatic drugs
- (2022) Marek Lommatzsch et al. LANCET
- Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
- (2022) Michael E Wechsler et al. Lancet Respiratory Medicine
- Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma – First Initiators and Switchers
- (2022) Simone Hashimoto et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
- (2022) Takanori Numata et al. Journal of Asthma and Allergy
- Overall response to anti-IL5/anti-IL5Rα treatment in severe asthma does not depend on initial bronchodilator responsiveness
- (2022) Carlo Mümmler et al. Journal of Allergy and Clinical Immunology-In Practice
- REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma
- (2022) Charles Pilette et al. Journal of Allergy and Clinical Immunology-In Practice
- Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
- (2022) Evan S. Dellon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
- (2021) Carlos Martínez-Rivera et al. BMC Pulmonary Medicine
- The relationship between FeNO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma
- (2021) A.P. Hearn et al. Journal of Allergy and Clinical Immunology-In Practice
- Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma
- (2021) Katrien Eger et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-world efficacy and safety of dupilumab use in the treatment of asthma
- (2021) Somaira Nowsheen et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial
- (2021) Steven G. Kelsen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
- (2021) Andrew Menzies-Gow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Joseph K Han et al. Lancet Respiratory Medicine
- Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab‐induced hypereosinophilia
- (2021) Marek Lommatzsch et al. ALLERGY
- Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
- (2021) William W. Busse et al. EUROPEAN RESPIRATORY JOURNAL
- Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP
- (2021) Ignaz Briegel et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
- (2021) Moritz Z Kayser et al. Journal of Asthma and Allergy
- Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
- (2021) Michael E. Wechsler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial
- (2021) Christopher E. Brightling et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)
- (2021) Eva Martínez-Moragón et al. BMC Pulmonary Medicine
- Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
- (2021) Andrew Menzies-Gow et al. Lancet Respiratory Medicine
- Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion
- (2021) Roland Buhl et al. Journal of Allergy and Clinical Immunology-In Practice
- Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab
- (2021) Tjeerd Veer et al. Clinical and Translational Allergy
- Successful treatment of refractory status asthmaticus with omalizumab: a case report
- (2021) Jan Benes et al. Allergy Asthma and Clinical Immunology
- Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial
- (2021) Claus Bachert et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab effectiveness and identification of super-responders in severe asthma
- (2020) Erin S. Harvey et al. EUROPEAN RESPIRATORY JOURNAL
- Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety
- (2020) Jermo Johannes van Toor et al. JOURNAL OF ASTHMA
- Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma
- (2020) Joanne E. Kavanagh et al. CHEST
- Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort
- (2020) Clairelyne Dupin et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Psoriasis bei Dupilumab-behandeltem atopischem Ekzem
- (2020) S. Senner et al. HAUTARZT
- Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature
- (2020) Florence Schleich et al. Journal of Allergy and Clinical Immunology-In Practice
- Real-world mepolizumab in the prospective severe asthma REALITI-A study – initial analysis
- (2020) Tim Harrison et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
- (2020) Philippe Gevaert et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Real-life experience with benralizumab during 6 months
- (2020) A. Padilla-Galo et al. BMC Pulmonary Medicine
- Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis
- (2020) Roberto Padoan et al. Journal of Allergy and Clinical Immunology-In Practice
- Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?
- (2020) Carlo Mümmler et al. Allergy Asthma and Clinical Immunology
- Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
- (2020) Joanne E. Kavanagh et al. CHEST
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
- (2020) Florence Roufosse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma
- (2020) Francesco Menzella et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis
- (2020) Vamsi P. Guntur et al. Journal of Allergy and Clinical Immunology-In Practice
- Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy
- (2020) Carlo Mümmler et al. Journal of Allergy and Clinical Immunology-In Practice
- Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma
- (2020) Joanne E. Kavanagh et al. ALLERGY
- Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
- (2020) Tim W Harrison et al. Lancet Respiratory Medicine
- Higher Blood Eosinophil Levels after Omalizumab Treatment Are Associated with Poorer Asthma Outcomes.
- (2019) Bruno Sposato et al. Journal of Allergy and Clinical Immunology-In Practice
- Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab
- (2019) Seiko Soeda et al. ALLERGOLOGY INTERNATIONAL
- The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
- (2019) Kenneth R. Chapman et al. ALLERGY
- Conjunctivitis in dupilumab clinical trials
- (2019) B. Akinlade et al. BRITISH JOURNAL OF DERMATOLOGY
- Epithelial cell–derived cytokines: more than just signaling the alarm
- (2019) Florence Roan et al. JOURNAL OF CLINICAL INVESTIGATION
- Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome
- (2019) Fei Li Kuang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis
- (2019) Kenchi Takenaka et al. ALLERGOLOGY INTERNATIONAL
- Combination biologic therapy for severe persistent asthma
- (2019) Gilbert Ortega et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
- (2019) Francesco Menzella et al. Therapeutics and Clinical Risk Management
- Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline
- (2019) Fernando Holguin et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
- (2019) Claus Bachert et al. LANCET
- Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab
- (2019) Luis A. Pérez de Llano et al. ALLERGY
- Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose
- (2019) Corrado Pelaia et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
- (2019) Audrey Le Floc’h et al. ALLERGY
- An expert consensus framework for asthma remission as a treatment goal
- (2019) Andrew Menzies-Gow et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case series
- (2019) Richard Paul Ramonell et al. Journal of Allergy and Clinical Immunology-In Practice
- Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
- (2018) Manali Mukherjee et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
- (2018) Bradley E. Chipps et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study
- (2018) Marc Humbert et al. EUROPEAN RESPIRATORY JOURNAL
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
- (2018) Klaus F. Rabe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
- (2018) Mario Castro et al. NEW ENGLAND JOURNAL OF MEDICINE
- A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab
- (2018) Takeshi Terashima et al. BMC Pulmonary Medicine
- Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
- (2018) Nora Drick et al. BMC Pulmonary Medicine
- Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
- (2018) J Mark FitzGerald et al. Lancet Respiratory Medicine
- Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
- (2018) Thomas B. Casale et al. Journal of Allergy and Clinical Immunology-In Practice
- Baseline Patient Factor Impact on the Clinical Efficacy of Benralizumab for Severe Asthma
- (2018) Eugene R. Bleecker et al. EUROPEAN RESPIRATORY JOURNAL
- Omalizumab Rescue Therapy for Refractory Status Asthmaticus
- (2018) Katrin Milger et al. ANNALS OF INTERNAL MEDICINE
- Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
- (2018) William W Busse et al. Lancet Respiratory Medicine
- Allergic bronchopulmonary aspergillosis successfully treated with benralizumab
- (2018) Seiko Soeda et al. Journal of Allergy and Clinical Immunology-In Practice
- Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases
- (2018) Zeynep Celebi Sozener et al. World Allergy Organization Journal
- Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
- (2017) Frank C. Albers et al. JOURNAL OF ASTHMA
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
- (2017) Michael E. Wechsler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
- (2017) Guy Brusselle et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
- (2017) Geoffrey L Chupp et al. Lancet Respiratory Medicine
- “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis
- (2017) Abdulaziz Alhossan et al. Journal of Allergy and Clinical Immunology-In Practice
- Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
- (2016) A. Magnan et al. ALLERGY
- Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
- (2016) Jonathan Corren et al. CHEST
- Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
- (2016) Leif Bjermer et al. CHEST
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients
- (2016) Marie Jachiet et al. Arthritis & Rheumatology
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
- (2016) Hector G Ortega et al. Lancet Respiratory Medicine
- Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases
- (2015) Ömür Aydın et al. ALLERGY AND ASTHMA PROCEEDINGS
- The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy
- (2015) Jennifer Namazy et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study
- (2015) Aikaterini Detoraki et al. JOURNAL OF ASTHMA
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis
- (2015) Astrid L. Voskamp et al. Journal of Allergy and Clinical Immunology-In Practice
- The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia
- (2014) H. Ortega et al. EUROPEAN RESPIRATORY JOURNAL
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)
- (2014) F. Schleich et al. RESPIRATORY MEDICINE
- Exploring the Effects of Omalizumab in Allergic Asthma
- (2013) Nicola A. Hanania et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
- (2013) Nicola A. Hanania et al. ANNALS OF INTERNAL MEDICINE
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2013) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects
- (2013) William Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma
- (2013) Michael C. Peters et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
- (2013) Marcus Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global asthma prevalence in adults: findings from the cross-sectional world health survey
- (2012) Teresa To et al. BMC PUBLIC HEALTH
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Allergic bronchopulmonary aspergillosis and omalizumab
- (2011) I. Tillie-Leblond et al. ALLERGY
- Effects of omalizumab in Aspergillus-associated airway disease
- (2011) L. A. Perez-de-Llano et al. THORAX
- Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
- (2010) Sophia Kim et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
- (2010) Roland Kolbeck et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Churg-Strauss Syndrome in Patients Treated With Omalizumab
- (2009) Michael E. Wechsler et al. CHEST
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started